How Ph.D. was paid
$1.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Incentive | Total |
|---|---|---|---|---|
| David H. Mack, Ph.D.President, Chief Executive Officer and Director | $628,461 | $752,320 | $284,410 | $1,665,191 |
| Deepika Jalota, Pharm.D.Chief Development Officer | $478,429 | $282,120 | $174,638 | $935,187 |
| Robert TicktinGeneral Counsel & Chief Operating Officer | $450,000 | $249,206 | $162,000 | $861,206 |
What changed and why
- $1.7MDavid H. Mack received total compensation of $1,665,191 in fiscal 2025.
- $4.8MCEO total compensation decreased significantly compared to the prior fiscal year total of $4,760,281.
- $284KNon-equity incentive plan compensation of $284,410 was paid to the CEO based on development, pipeline, and corporate goals.
- Stock and option awards for executives were granted under the 2020 Equity Incentive Plan.
- 63%Approximately 63 percent of shares voted abstained or voted against the advisory say-on-pay proposal at the 2025 annual meeting.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.